Preparation of arsenic trioxide-loaded microemulsion and its enhanced cytotoxicity on MCF-7 breast carcinoma cell line.
In this study, an injectable microemulsion of arsenic trioxide (As2O3-M) was prepared for intratumoral injection and the suppressive effect of As2O3-loaded microemulsion on human breast cancer cells MCF-7 was compared with those of a solution of the drug. Microemulsion was made up of soybean oil as oil phase, a mixture of Brij 58 and Span 80 as surfactants, absolute ethanol as cosurfactant, and bidistilled water containing As2O3 solution as the aqueous phase. Microemulsion formulation contains 5 x 10(-6) M As2O3. The pH of As2O3-M was adjusted to 7.35 +/- 0.1 and the physicochemical stability of the formulation was observed. The particle size distribution and zeta potential of As2O3-M were measured by Zetasizer 3000 HSA. The mean droplet diameters of As2O3-M were determined as 8.6 +/- 0.4 nm. As2O3-M exhibited 13.1 +/- 0.9 mV zeta potential. The formulation was physically stable for 12 months at room temperature when kept in ampule forms, as well as after autoclaving at 110 degrees C for 30 min. The antitumor effects of As2O3-M were examined on human breast cancer cells MCF-7. It was clearly demonstrated that As2O3-M had a significant cytotoxic effect on breast cancer cell lines, and the cytotoxic effect of As2O3-M was significantly more than that of regular As2O3 solutions. Even approximately 3000 times diluted microemulsion formulation loaded with 5 x 10(-6) M As2O3 showed a cytotoxic effect. As a result, this diluted concentration (approximately 1.6 x 10(-9) M) was found 1000 times more effective than regular As2O3 solutions (5 x 10(-6) M). According to the in vitro cytotoxicity studies, we concluded that when As2O3 was incorporated into the microemulsion (As2O3-M), which is a new drug carrier system, it suppresses tumor cell growth on multiple tumor lines. These results indicate that As2O3-M may exert a low cytotoxic effect on normal cells and may be effective as an antitumor agent that induces apoptosis.
Karasulu
H Yeşim
HY
Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Ege, Izmir, Turkey. karasuluy@pharm.ege.edu.tr
Karabulut
Bülent
B
Kantarci
Gülten
G
Ozgüney
Işik
I
Sezgin
Canfeza
C
Sanli
Ulus Ali
UA
Göker
Erdem
E
D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000008:administration & dosage / Q000138:chemical synthesis*; D045744:Cell Line, Tumor; D004305:Dose-Response Relationship, Drug; D004337:Drug Carriers / Q000008:administration & dosage / Q000138:chemical synthesis* / Q000633:toxicity*; D004655:Emulsions; D006801:Humans; D015552:Injections, Intralesional; D010087:Oxides / Q000008:administration & dosage / Q000138:chemical synthesis* / Q000633:toxicity*; D010316:Particle Size
D001152:Arsenicals; D004337:Drug Carriers; D004655:Emulsions; D010087:Oxides; D000077237:Arsenic Trioxide